- Hypermobile Neck Exercises - 8 November 2026
- Swollen legs and hypermobility: pooling, lymphoedema and lipoedema - 4 November 2026
- Walking with fibromyalgia - 2 November 2026
This article is part of our comprehensive guide to living with fibromyalgia.
Amitriptyline is usually the first tablet anybody with fibromyalgia gets offered, at a dose so small you’d be forgiven for wondering whether anybody means it. The leaflet talks about depression, the appointment lasted ten minutes, and nobody explained either.
The short version. It helps some people a bit, for a few weeks, and the evidence for it is older and shakier than how often it’s prescribed would suggest. Give it about six weeks at a dose you can tolerate, expect the side effects to turn up before any benefit does, and don’t stop it overnight.
This article covers:
ToggleWhy an antidepressant, and why such a small dose?
Amitriptyline leaves more serotonin and noradrenaline hanging about between nerve cells. At high doses that’s aimed at mood. At low doses it’s aimed at the descending system, the wiring that runs from the brainstem down into the spinal cord and decides how much of the incoming signal from your joints and tissues gets passed further up. Same drug, different job, which is why the leaflet in the box describes a condition you’ve never been told you have.
So being handed an antidepressant isn’t a verdict that your pain is in your head. It’s just what this drug turned out to do at low doses.
It also blocks acetylcholine, the messenger behind saliva, gut movement and a fair bit of attention and memory. That’s what anticholinergic means, and it’s where the dry mouth, the sluggish gut and the head full of wool come from.
Does it actually help the pain?
Probably a bit, for some people, and nobody can tell you how much with any confidence.
The most recent big look at this is a 2024 overview of the Cochrane reviews of drugs for fibromyalgia, 87 trials and over 17,000 people between them. Pool the amitriptyline trials at 25 or 50 mg and roughly one extra person in four gets substantial pain relief compared with placebo [1]. That sounds decent until you read the rest. The same authors flagged those trials as high risk of bias and open to publication bias, which is the habit of trials that found nothing never getting written up, and they put amitriptyline on their list of drugs with no trustworthy evidence [1]. The trials themselves are small, mostly from before 2000, short, and used outcomes nobody would design a trial around now [2].
The biggest of them is the one that stings. It followed 208 adults for six months, and improvement on amitriptyline rose to 36% by the end, but placebo had climbed to 19% as well, and long term benefit couldn’t be shown [3].
None of that means it does nothing. It means the number is softer than it looks, and the only way to find out whether you’re one of the people it helps is a fair trial of it.

Or is it really the sleep?
This is what people ask a month in. The pain’s still there, but they’re sleeping, and they want to know whether that counts.
A 2025 review of sleep treatments in fibromyalgia found eight amitriptyline trials, every one of which measured sleep by asking people to mark a line. Six could be pooled, and the effect on sleep wasn’t statistically significant, with the trials disagreeing wildly. Take out the one trial that disagreed most and it became significant [4]. That’s not a drug with a reliable sleep effect. It’s a drug whose sleep effect depends on which trial you happen to read.
Two more things from that review. In the eight week study that wired people up overnight, people rated their sleep better while the recording showed no improvement, and the brief surfacings out of deep sleep actually got more frequent [4]. And in fibromyalgia, that line people mark for sleep tracks pain more closely than it tracks sleep disturbance [4], so a better sleep score is partly a pain score.
None of which makes better sleep worthless. Sleep is most of what makes the next day survivable. It just isn’t proof the pain is being dealt with in the background, so if sleep is the only thing that’s moved by week six, say so at the review.
Is 10 mg a real dose?
Yes. It’s a starting dose, and it’s meant to be. The fibromyalgia evidence sits mostly at 25 mg, where a 2008 review of the trials found a response in pain, sleep, fatigue and how people rated themselves overall at six to eight weeks. In the same review 50 mg didn’t beat placebo, and nothing supported going on past eight weeks [5].
That’s roughly where real prescribing lands. In a German clinic cohort of 156 people with fibromyalgia, the median amitriptyline dose was 25 mg, and 84% of those on it were taking somewhere between 10 and 50 mg [6].
Going higher is where it gets genuinely unsettled. In one small crossover trial in assorted chronic pain, not fibromyalgia and with no placebo arm, 75 mg gave more pain relief than 25 mg, and more than twice as many people got a dry mouth on it, 17 of 27 against 8 of 26 [7]. That’s a reason to think going up might help you. It isn’t evidence that it will, and it’s a conversation with your prescriber rather than a ladder you climb on your own.
How long before you know?
About six weeks at a dose you can tolerate, which is how long the typical trial of this drug ran [8]. Not ten days. Not a fortnight. You take it every night whether the day was bad or not, and you judge it on the month, not the evening.
The catch is that the side effects don’t wait for the benefit. Across 23 randomised trials of amitriptyline for a range of conditions, anticholinergic side effects, the dry mouth and drowsiness family, turned up in roughly one extra person for every three treated compared with placebo, and the dose didn’t predict how often they happened [9]. So the small dose doesn’t buy you out of them. In that German cohort, amitriptyline was the drug people had most often given up on, and side effects were the commonest reason [6].
What people describe is waking up wrung out and foggy, not fit to drive, and that’s usually when they quietly stop, weeks before anybody could tell whether it was working. Amitriptyline hangs about in the body a long time, so a tablet at eleven at night is still partly with you at breakfast. Timing and dose are the only two levers, and both belong to your prescriber. If the mornings are beating you, ring them before you stop, not instead of it.
What it costs you
Weight. It’s the side effect people ask about most and the one with the least behind it. Weight gain turns up in chronic pain studies of antidepressants far less consistently than dry mouth or drowsiness, so nobody can tell you how often it happens at low doses [10]. Which isn’t the same as no risk. Weigh yourself the week you start and write it down. In three months you’ll know rather than guess.
Coming off. Stopping can bring on withdrawal symptoms, usually within days [11], and across antidepressants the usual ones are dizziness, nausea, poor sleep and mood changes [12]. Most of that data comes from people taking it for depression, not 10 to 25 mg for pain, so how often it happens at our doses isn’t well pinned down [13]. Come off it with a planned taper agreed with your prescriber, not because the packet ran out on a Thursday. And if you felt rough for longer than anyone said you would, you weren’t imagining it.
The dementia headline. It comes from amitriptyline being strongly anticholinergic. In English GP records covering over 280,000 people aged 55 and over, those with the heaviest use of anticholinergic antidepressants had about 1.3 times the odds of a dementia diagnosis [14]. That’s an association in mostly older people, not a trial, and the reasons people get prescribed these drugs can be tangled up with dementia risk in the first place. In a Dutch cohort of 5,511 older adults, tricyclics carried a modest rise in risk, but more of the drug didn’t mean more risk [15]. And the studies that would settle it, cutting people’s anticholinergic load and watching what happens, haven’t produced enough good evidence either way [16]. So it’s a real association, not proof of cause. If it worries you on a long term prescription, raise it at a review, weighed against what you’d be going back to without it.
So, should you take it?
If you’ve been handed it, give it a proper go. Get to a dose you can tolerate, give it about six weeks, and keep a two line note each week of how you slept and where the pain sat, because nobody remembers week one accurately by week six. If nothing has moved by then, that’s an answer, and it’s worth going back and saying so.
What it isn’t, at any dose, is the treatment. At best it takes the edge off and buys you some sleep while you get on with the slower work, which is rebuilding capacity and settling a nervous system that’s been running hot for years.
Adam

References
[1] Moore, A., Bidonde, J., Fisher, E., Häuser, W., Bell, R.F., Perrot, S. et al. (2024) ‘Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews’, Rheumatology. https://doi.org/10.1093/rheumatology/keae707
[2] Moore, R.A., Derry, S., Aldington, D., Cole, P. and Wiffen, P.J. (2015) ‘Amitriptyline for fibromyalgia in adults’, Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd011824
[3] Carette, S., Bell, M.J., Reynolds, W.J., Haraoui, B., McCain, G.A., Bykerk, V.P. et al. (1994) ‘Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia’, Arthritis & Rheumatism. https://doi.org/10.1002/art.1780370106
Read More[4] Pathak, A., Kelleher, E.M., Brennan, I., Amarnani, R., Wall, A., Murphy, R. et al. (2025) ‘Treatments for enhancing sleep quality in fibromyalgia: a systematic review and meta-analysis’, Rheumatology. https://doi.org/10.1093/rheumatology/keaf147
[5] Nishishinya, B., Urrutia, G., Walitt, B., Rodriguez, A., Bonfill, X., Alegre, C. et al. (2008) ‘Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy’, Rheumatology. https://doi.org/10.1093/rheumatology/ken317
[6] Aster, H.C., Evdokimov, D., Braun, A., Üçeyler, N. and Sommer, C. (2022) ‘Analgesic Medication in Fibromyalgia Patients: A Cross-Sectional Study’, Pain Research and Management. https://doi.org/10.1155/2022/1217717
[7] McQuay, H.J., Carroll, D. and Glynn, C.J. (1993) ‘Dose-response for analgesic effect of amitriptyline in chronic pain’, Anaesthesia. https://doi.org/10.1111/j.1365-2044.1993.tb06943.x
[8] Moore, R.A., Derry, S., Aldington, D., Cole, P. and Wiffen, P.J. (2012) ‘Amitriptyline for neuropathic pain and fibromyalgia in adults’, Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008242.pub2
[9] Brueckle, M.S., Thomas, E.T., Seide, S.E., Pilz, M., Gonzalez-Gonzalez, A.I., Dinh, T.S. et al. (2023) ‘Amitriptyline’s anticholinergic adverse drug reactions: a systematic multiple-indication review and meta-analysis’, PLOS ONE. https://doi.org/10.1371/journal.pone.0284168
[10] Riediger, C., Schuster, T., Barlinn, K., Maier, S., Weitz, J. and Siepmann, T. (2017) ‘Adverse Effects of Antidepressants for Chronic Pain: A Systematic Review and Meta-analysis’, Frontiers in Neurology. https://doi.org/10.3389/fneur.2017.00307
[11] Haddad, P.M. (2001) ‘Antidepressant Discontinuation Syndromes’, Drug Safety. https://doi.org/10.2165/00002018-200124030-00003
[12] Henssler, J., Heinz, A., Brandt, L. and Bschor, T. (2019) ‘Antidepressant Withdrawal and Rebound Phenomena’, Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2019.0355
[13] Zhang, M.M., Tan, X., Zheng, Y.B., Zeng, N., Li, Z., Horowitz, M.A. et al. (2024) ‘Incidence and risk factors of antidepressant withdrawal symptoms: a meta-analysis and systematic review’, Molecular Psychiatry. https://doi.org/10.1038/s41380-024-02782-4
[14] Coupland, C.A.C., Hill, T., Dening, T., Morriss, R., Moore, M. and Hippisley-Cox, J. (2019) ‘Anticholinergic Drug Exposure and the Risk of Dementia’, JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2019.0677
[15] vom Hofe, I., Stricker, B.H., Vernooij, M.W., Ikram, M.K., Ikram, M.A. and Wolters, F.J. (2024) ‘Antidepressant use in relation to dementia risk, cognitive decline, and brain atrophy’, Alzheimer’s & Dementia. https://doi.org/10.1002/alz.13807
[16] Taylor-Rowan, M., Alharthi, A.A., Noel-Storr, A.H., Myint, P.K., Stewart, C., McCleery, J. et al. (2022) ‘Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment’, Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd015405


